DSpace Repository

COVİD-19 PANDEMİSİNİN KARDİYOVASKÜLER ETKİLERİ

Show simple item record

dc.creator KARABACAK, Mustafa; SÜLEYMAN DEMİREL ÜNİVERSİTESİ
dc.date 2021-06-05T00:00:00Z
dc.date.accessioned 2021-12-03T11:47:05Z
dc.date.available 2021-12-03T11:47:05Z
dc.identifier https://dergipark.org.tr/tr/pub/sdutfd/issue/62643/915484
dc.identifier 10.17343/sdutfd.915484
dc.identifier.uri http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/94273
dc.description Koronavirüs hastalığı-2019 (COVID-19), DSÖ tarafından Mart 2020 de Pandemi olarak kabul edildi ve etken “Ciddi Akut Solunumsal Sendrom-Koronavirüs-2” (SARS-CoV-2) olarak isimlendirildi. SARS-CoV2 enfeksiyonu, anjiyotensin dönüştürücü enzim 2'nin (ACE2) virüs yüzeyine diken proteinlerle bağlanmasıyla hücreye penetre olmaktadır. Çalışmalarda COVID-19 enfeksiyonuna, kardiyovasküler hastalıkların sıklıkla eşlik ettiği ve kötü prognozla ilişkili olduğu gösterilmiştir. COVİD-19 enfeksiyonu miyokardit, kalp yetmezliği, akut koroner sendromlar, aritmi, kardiyojenik şok gibi bazı kardiyovasküler komplikasyonlara neden olabilir. Bu olumsuz kardiyovasküler komplikasyonlar, ACE2 yolu ile doğrudan miyokardiyal hasar veya SARS CoV-2'nin dolaylı kardiyak etkileri nedeniyle ortaya çıkar. Özellikle hiperenflamasyona bağlı olarak gelişen sitokin fırtınası kalp hasarından sorumlu olabilir. COVID-19 ile enfekte olmuş hastaların % 25'inden fazlası miyokardiyal hasara sahiptir. Bu nedenle, COVID-19 ile enfekte olan hastalar, hastanede kaldıkları süre boyunca, mutlaka miyokardiyal hasar açısından değerlendirilmelidir.
dc.description The coronavirus disease-2019 (COVID-19) has rapidly developed into a global pneumonia pandemic. SARS-CoV2 infection is occurred by attaching angiotensin converting enzyme 2 (ACE2)with spike proteins on the surface of virus. Cardiovascular diseases is most common comorbidity of COVID-19 patients and is closely related to poor prognosis. COVİD-19 infection may cause a some of cardiovascular complications such as myocardit, heart failure, acute coronary syndroms, arrhythmia, cardiojenic shock. These unfavourable cardiovascular complications occur due to the direct myocardial injury by ACE2 pathway or indirect cardiac effects of SARS CoV-2. Especially, Cytokine storm that develops especially due to hyper-inflammation may be responsible for cardiac damage. More than 25% of COVID-19 infected patient have myocardial injury .Thus, COVID-19 infected patients must be followed for myocardial injury during the hospital stay.
dc.format application/pdf
dc.language tr
dc.publisher Süleyman Demirel Üniversitesi
dc.publisher Süleyman Demirel University
dc.relation https://dergipark.org.tr/tr/download/article-file/1704755
dc.source Volume: COVID-19 Özel Sayı, Issue: 1 229-233 en-US
dc.source 1300-7416
dc.source 2602-2109
dc.source SDÜ Tıp Fakültesi Dergisi
dc.subject COVİD-19,PANDEMİ,Kardiyovasküler hastalıklar
dc.subject COVİD-19,Pandemic,Cardiovascular diseases
dc.title COVİD-19 PANDEMİSİNİN KARDİYOVASKÜLER ETKİLERİ tr-TR
dc.title CARDIOVASCULAR EFFECTS OF COVID-19 PANDEMIA en-US
dc.type info:eu-repo/semantics/article
dc.citation Referans 1. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020 Feb 7.2. Referans 2. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods in Molecular Biology. 2015;1282:1-23
dc.citation Referans 3.Zhu N, Zhang D, Wang W, Li X, Song J, Yang B, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl j Med. 2020;382:727-33
dc.citation Referans 4. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med 2020 Mar 17.
dc.citation Referans 5. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med 2020 Mar 10.
dc.citation Referans 6. Clerkin Kj, Fried jA, Raikhelkar j, Sayer G, Griffen MJ, Masoumi A, et al. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease Circulation. 2020; 10.1161.
dc.citation Referans 7. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020 Feb 28.
dc.citation Referans 8. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol 2020 Mar 11.
dc.citation Referans 9. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). jAMA Cardiol. 2020.
dc.citation Referans 10. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. jAMA Cardiol. 2020.
dc.citation Referans 11. Zhou F, Yu T, Du R, Fun G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-62.
dc.citation Referans 12. Han Y. Initial COVID-19 affecting cardiac patients in China, European Heart journal, ehaa257 .
dc.citation Referans 13. Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Bondi-Zoccai G, et al. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic. Journal of the American College of Cardiology (2020).
dc.citation Referans 14. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. j Thromb Haemost. 2020;18:844-7.
dc.citation Referans 15. Vallance P, Collier j, Bhagat K. Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link? Lancet. 1997;349:1391-2.
dc.citation Referans 16. Huang C, Wang Y, Li X, Ren L, Zhou J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395: 497-506.
dc.citation Referans 17. Alhawassi TM, Krass I, Pont LG. Prevalence, prescribing and barriers to effective management of hypertension in older populations:a narrative review. J Pharm Policy Pract 2015;8:24.
dc.citation Referans 18. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. The journal of Pathology. 2004;203:631-7.
dc.citation Referans 19. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga ES, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417:822-8.
dc.citation Referans 20. Vaduganathan M, Vardeny O, Michel T, Mc-Murray jjV, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl j Med. 2020.
dc.citation Referans 21. Li XC, Zhang J, Zhuo JL. The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases. Pharmacol Res 2017;125:21–38
dc.citation Referans 22. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004;203:631–7.
dc.citation Referans 23. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 2005;111:2605–10.
dc.citation Referans 24. Ocaranza MP, Godoy I, Jalil JE, Varas M, Collantes P, Pinto M, et al. Enalapril attenuates downregulation of Angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat. Hypertension 2006;48:572–8.
dc.citation Referans 25. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 2004;43:970–6.
dc.citation Referans 26. Henry C, Zaizafoun M, Stock E, Ghamande S, Arroliga AC, White HD. Impact of angiotensin-converting enzyme inhibitors and statins on viral pneumonia. Proc (Bayl Univ Med Cent) 2018;31:419–23.
dc.citation Referans 27. Simone G. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers. 2020 March.
dc.citation Referans 28. Tang N, Li D, Wang X, Sun z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. j Thromb Haemost. 2020;18:844-7.
dc.citation Referans 29. Corrales-Medina VF, Alvarez KN, Weissfeld LA, Angus CD, Chirinos AJ, Chang HCC, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. jAMA. 2015;313:264-74.
dc.citation Referans 30. Udell JA, Zawi R, Bhatt DL, Jahromi KM, Gaughran F, Phroumtikul A, et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a metaanalysis. jAMA. 2013;310:1711-20.
dc.citation Referans 31. Vallance P, Collier j, Bhagat K. Infection, inflammation,and infarction: does acute endothelial dysfunction pro-vide a link? Lancet. 1997;349:1391-2.
dc.citation Referans 32. Chapman AR, Shah AS, Lee KK, Anand A, Francis O, Adamson P, et al. Long-Term Outcomes in Patients With Type 2 Myocardial Infarction and Myocardial Injury. Circulation. 2018;137:1236-45.
dc.citation Referans 33. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020:S0140-6736;30566-3.
dc.citation Referans 34. Zanuzzi JL. Troponin and BNP Use in COVID-19 American College of Cardiology.. Accessed Mar 23, 2020.
dc.citation Referans 35. Choudry FA, Hamshere MS, Rathod SK, Akhtar MM, Archbold RA, Guttman PO, et al. J Am Coll Cardiol. 2020 Sep 8;76(10):1168-1176.
dc.citation Referans 36. Care I, Frankie C, Wong A, Lam Y. Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on ST-Segment-Elevation Myocardial Infarction Care in Hong Kong, China. 2020; 2019(April):2019-2021.
dc.citation Referans 37. Zeng J, Huang J, Pan L. How to balance acute myocardial infarction and COVID-19: the protocols from Sichuan Provincial People’s Hospital. Intensive Care Med. 2020:10-12.
dc.citation Referans 38. Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. JAMA 2020 Mar 19.
dc.citation Referans 39. Buzon J, Roignot O, Lemoine S, Perez P, Kimmoun A, Levy B, et al. Takotsubo Cardiomyopathy Triggered by Influenza A Virus. Intern Med 2015;54:2017–9.
dc.citation Referans 40. Zhu Z. Comparison of clinical and imaging features between patients with heart failure and new coronavirus pneumonia during the epidemic. Chinese Journal of Cardiovascular Disease, 2020, 48
dc.citation Referans 41. Bajwa EK, Januzzi JL, Gong MN, Thompson BT, Christiani DC. Prognostic value of plasma N-terminal probrain natriuretic peptide levels in the acute respiratory distress syndrome. Crit Care Med 2008;36:2322–7.
dc.citation Referans 42. Repessé X, Charron C, Vieillard-Baron A. Acute cor pulmonale in ARDS: rationale for protecting the right ventricle. Chest 2015;147:259–65.
dc.citation Referans 43. Channappanavar R, Perlman S. Pathogenic human koronavirüs infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol 2017;39:529–39.
dc.citation Referans 44. Zeng JH, Liu Y, Yuan J, Wang F, Wu W, Li XJ, et al. First Case of COVID-19 Infection with Fulminant Myocarditis Complication: Case Report and Insights. Preprints Mar 11, 2020.
dc.citation Referans 45. Frederich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakije P, Cooper TL, et al. Cardiovascular magnetic resonance in myocarditis. J Am Coll Cardiol. 2009;53(17): 1475-87.
dc.citation Referans 46. Cooper LT Jr. Myocarditis. N Engl J Med.2009;360(15):1526-38.


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account